Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 153,736,224
  • Shares Outstanding, K 1,596,430
  • Annual Sales, $ 25,638 M
  • Annual Income, $ 5,953 M
  • 36-Month Beta 1.52
  • Price/Sales 6.01
  • Price/Cash Flow 17.24
  • Price/Book 23.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
92.71 +5.00%
on 11/15/17
98.87 -1.54%
on 12/13/17
+2.23 (+2.34%)
since 11/13/17
3-Month
83.19 +17.02%
on 09/27/17
98.87 -1.54%
on 12/13/17
+8.88 (+10.04%)
since 09/13/17
52-Week
59.27 +64.25%
on 01/30/17
98.87 -1.54%
on 12/13/17
+35.36 (+57.04%)
since 12/13/16

Most Recent Stories

More News
Roche/AbbVie Report Positive Phase III Results on Venclexta

Roche (RHHBY) announced positive results from a pivotal phase III study, MURANO, evaluating Venclexta plus Rituxan compared to bendamustine plus Rituxan (BR) for the treatment of relapsed or refractory...

NVS : 84.66 (+0.24%)
ABBV : 97.35 (+1.09%)
RHHBY : 30.5000 (+0.53%)
AMGN : 177.38 (+0.64%)
Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug

Bristol-Myers Squibb Company (BMY) announced positive data from an ongoing phase II study on leukemia drug Sprycel in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk...

SCMP : 16.50 (+1.23%)
ABBV : 97.35 (+1.09%)
HALO : 20.80 (+6.29%)
BMY : 63.47 (+0.30%)
Novartis Announces Positive Data on Sickle Cell Disease Drug

Novartis (NVS) announced positive data from a phase II study, SUSTAIN, on pipeline candidate crizanlizumab which deferred the time to first sickle cell pain crisis (SCPC) in patients compared to placebo...

SCMP : 16.50 (+1.23%)
NVS : 84.66 (+0.24%)
ABBV : 97.35 (+1.09%)
RHHBY : 30.5000 (+0.53%)
AbbVie Announces Phase 3 Study of VENCLEXTA(TM)/ VENCLYXTO(TM) (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint

AbbVie (NYSE: ABBV), a research and development based global biopharmaceutical company, today announced the first presentation of efficacy and safety results from MURANO, an international, multicenter,...

ABBV : 97.35 (+1.09%)
IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data on the biologic and cellular mechanisms of IMBRUVICA® (ibrutinib) in patients with chronic graft-versus-host disease (cGVHD),...

ABBV : 97.35 (+1.09%)
IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced pooled analysis results of the longest follow-up data to date in Bruton's tyrosine kinase (BTK) inhibition for relapsed/refractory...

ABBV : 97.35 (+1.09%)
IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new three-year follow-up data from the RESONATE(TM)-2 study (PCYC-1115/1116), which found that previously-untreated chronic lymphocytic...

ABBV : 97.35 (+1.09%)
AbbVie/J&J's Imbruvica Succeeds in Combo Study with Rituxan

AbbVie (ABBV) J&J's combination study evaluating Imbruvica in Waldenstrom's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, meets primary endpoint.

JNJ : 142.89 (+0.20%)
ABBV : 97.35 (+1.09%)
RHHBY : 30.5000 (+0.53%)
AMGN : 177.38 (+0.64%)
Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data

Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.

RARE : 45.19 (+1.53%)
CLVS : 63.77 (+1.98%)
ABBV : 97.35 (+1.09%)
REGN : 386.67 (+1.30%)
AMGN : 177.38 (+0.64%)
BIIB : 330.71 (+0.90%)
RVNC : 34.10 (-0.29%)
AbbVie Psoriasis Candidate Succeeds in 4th Phase III Study

AbbVie (ABBV) announces data from a phase III study on risankizumab, which shows that a significant portion of plaque psoriasis patients treated with risankizumab achieved high levels of skin clearance....

JNJ : 142.89 (+0.20%)
ABBV : 97.35 (+1.09%)
HLUYY : 48.3400 (-0.17%)
AMGN : 177.38 (+0.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Key Turning Points

2nd Resistance Point 99.88
1st Resistance Point 98.61
Last Price 97.35
1st Support Level 96.34
2nd Support Level 95.34

See More

52-Week High 98.87
Last Price 97.35
Fibonacci 61.8% 83.74
Fibonacci 50% 79.07
Fibonacci 38.2% 74.40
52-Week Low 59.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.